NYSE:AORTMedical Equipment
Should Artivion’s Lowered 2026 Guidance and Endospan Deal Require Action From Artivion (AORT) Investors?
In early May 2026, Artivion, Inc. reported first‑quarter revenue of US$116.34 million, up from US$98.98 million a year earlier, and moved from a small net loss to a net income of US$1.42 million while also announcing plans to acquire Endospan following FDA approval of the NEXUS Aortic Arch System.
Despite this topline growth and portfolio expansion, Artivion missed profit expectations and lowered its full‑year 2026 revenue and adjusted EBITDA guidance, highlighting near‑term operational...